TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Skills-based RCT for Physical Activity Using Peer Mentors
Brief Summary: This approach will train peer mentors to deliver a culturally appropriate intervention and provide social support that is critical for facilitating and sustaining health behavior change. The objective is to compare the efficacy of an innovative healthy lifestyle skills mentoring program (Mentored Planning to be Active \[MBA\]) to a teacher led program (PBA) for increasing physical activity in Appalachian high school teens. MBA emphasizes the social determinants of health by using a social networking approach that trains peer mentors to support targeted teens


Options:
A: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Challenge! | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Challenge!; Assigned to Arm(s): Intervention group
B: Arm Label: ACTION PAC Behavioral Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: ACTION PAC, Behavioral: Communication with parents | Arm Label: Comparison; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Communication with parents | Intervention Type: BEHAVIORAL; Name: ACTION PAC; Assigned to Arm(s): ACTION PAC Behavioral Intervention | Intervention Type: BEHAVIORAL; Name: Communication with parents; Assigned to Arm(s): ACTION PAC Behavioral Intervention, Comparison
C: Arm Label: Mentoring to be Active; Type: EXPERIMENTAL; Interventions: Behavioral: Mentoring to be Active with Accelerometers | Arm Label: Planning to be Active; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Planning to be Active with Accelerometers | Arm Label: Peer Mentors; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: High School Teachers; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mentoring to be Active with Accelerometers; Assigned to Arm(s): Mentoring to be Active | Intervention Type: BEHAVIORAL; Name: Planning to be Active with Accelerometers; Assigned to Arm(s): Planning to be Active
D: Arm Label: Gardening; Type: EXPERIMENTAL; Interventions: Other: Garden | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Garden; Assigned to Arm(s): Gardening

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assessing the Effectiveness of Mass Drug Administration (MDA) With Dihydroartemisinin + Piperaquine for Reducing Malaria Parasite Infection Prevalence and Incidence in Southern Province Zambia
Brief Summary: To quantify the relative effectiveness, cost, and cost-effectiveness of fMDA and MDA with DHAp against no mass treatment for reducing P. falciparum parasite prevalence, confirmed OPD malaria case incidence and cohort infection incidence in areas of high and low malaria transmission and in a program-relevant manner that will permit adoption and adaptation for wider-scale deployment.


Options:
A: Arm Label: Participants; Type: OTHER; Interventions: Drug: Dihydroartemisinin-piperaquine | Intervention Type: DRUG; Name: Dihydroartemisinin-piperaquine; Assigned to Arm(s): Participants
B: Arm Label: MDA with DHAp and SLD Primaquine; Type: EXPERIMENTAL; Interventions: Drug: MDA with DHAp and SLD Primaquine | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: MDA with DHAp and SLD Primaquine; Assigned to Arm(s): MDA with DHAp and SLD Primaquine
C: Arm Label: malaria elimination using DP and low-dose primaquine; Type: EXPERIMENTAL; Interventions: Drug: malaria elimination using DP and low-dose primaquine | Arm Label: Control villages; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: malaria elimination using DP and low-dose primaquine; Assigned to Arm(s): malaria elimination using DP and low-dose primaquine
D: Arm Label: MDA with DHAp (Eurartesim); Type: EXPERIMENTAL; Interventions: Drug: MDA with DHAp (Eurartesim) | Arm Label: Focal MDA with DHAp (Eurartesim); Type: EXPERIMENTAL; Interventions: Drug: Focal MDA with DHAp (Eurartesim) | Arm Label: Standard of Care (Control); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: MDA with DHAp (Eurartesim); Assigned to Arm(s): MDA with DHAp (Eurartesim) | Intervention Type: DRUG; Name: Focal MDA with DHAp (Eurartesim); Assigned to Arm(s): Focal MDA with DHAp (Eurartesim)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of the Respiratory Rehabilitation Exercise Training Package in Hospitalized Elderly Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Randomized Control Trial
Brief Summary: The purpose of this randomized controlled trial was to evaluate the effects of a respiratory rehabilitation exercise training package on dyspnea, cough, exercise tolerance, and sputum expectoration of hospitalized elderly patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Using purposive sampling, 61 participants were recruited and randomly assigned to either the experimental group (n = 30) or the control group (n = 31). The experimental group participants received the respiratory rehabilitation exercise training twice a day and 10-30 minutes per session for four days. The control group participants received usual care and health education. Data were collected at baseline and at the end of the four-day intervention.


Options:
A: Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Diaphragmatic breathing training; Type: EXPERIMENTAL; Interventions: Other: Diaphragmatic breathing training | Intervention Type: OTHER; Name: Diaphragmatic breathing training; Assigned to Arm(s): Diaphragmatic breathing training
B: Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: inspiratory pressure training group; Type: EXPERIMENTAL; Interventions: Device: inspiratory pressure training group | Arm Label: mixed training group; Type: EXPERIMENTAL; Interventions: Device: mixed training group | Intervention Type: DEVICE; Name: inspiratory pressure training group; Assigned to Arm(s): inspiratory pressure training group | Intervention Type: DEVICE; Name: mixed training group; Assigned to Arm(s): mixed training group
C: Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Behavioral: Respiratory rehabilitation exercise training | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Respiratory rehabilitation exercise training; Assigned to Arm(s): Experimental group
D: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of the Respiratory Rehabilitation Exercise Training Package in Hospitalized Elderly Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Randomized Control Trial
Brief Summary: The purpose of this randomized controlled trial was to evaluate the effects of a respiratory rehabilitation exercise training package on dyspnea, cough, exercise tolerance, and sputum expectoration of hospitalized elderly patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Using purposive sampling, 61 participants were recruited and randomly assigned to either the experimental group (n = 30) or the control group (n = 31). The experimental group participants received the respiratory rehabilitation exercise training twice a day and 10-30 minutes per session for four days. The control group participants received usual care and health education. Data were collected at baseline and at the end of the four-day intervention.


Options:
A: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: EPR; Type: EXPERIMENTAL; Interventions: Other: Early pulmonary rehabilitation (EPR) | Intervention Type: OTHER; Name: Early pulmonary rehabilitation (EPR); Assigned to Arm(s): EPR
B: Arm Label: comprehensive care programme; Type: ACTIVE_COMPARATOR; Interventions: Other: Comprehensive care programme | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Comprehensive care programme; Assigned to Arm(s): comprehensive care programme
C: Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Behavioral: Respiratory rehabilitation exercise training | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Respiratory rehabilitation exercise training; Assigned to Arm(s): Experimental group
D: Arm Label: Activity-Self Management; Type: EXPERIMENTAL; Interventions: Behavioral: Self-Management and Motivational Interviewing | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Self-Management and Motivational Interviewing; Assigned to Arm(s): Activity-Self Management

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Anagliptin and Sitagliptin on Low-density Lipoprotein Cholesterol in Patients With Type 2 Diabetes and Cardiovascular Risk Factors: Randomized Controlled Trial
Brief Summary: The purpose of this study is to determine whether Anagliptin or Sitagliptin are effective in reducing the low-density lipoprotein cholesterol in patients with type 2 diabetes and cardiovascular risk factors on statin.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lenograstim (GRANOCYTE)=GCSF, Drug: Sitagliptin (Januvia) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sodium Chloride (NaCl) 0.9 %, Drug: Gelatin | Intervention Type: DRUG; Name: Lenograstim (GRANOCYTE)=GCSF; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sitagliptin (Januvia); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sodium Chloride (NaCl) 0.9 %; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Gelatin; Assigned to Arm(s): 2
B: Arm Label: 1 Original Lifestyle; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: DPPOS Boost Lifestyle, Behavioral: Intensive Lifestyle Group Session | Arm Label: 2 Original Metformin; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Drug: Metformin, Behavioral: Intensive Lifestyle Group Session | Arm Label: 3 Original Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: Intensive Lifestyle Group Session | Intervention Type: BEHAVIORAL; Name: DPPOS Group Lifestyle; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 2 Original Metformin | Intervention Type: BEHAVIORAL; Name: DPPOS Boost Lifestyle; Assigned to Arm(s): 1 Original Lifestyle | Intervention Type: BEHAVIORAL; Name: Intensive Lifestyle Group Session; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo
C: Arm Label: Canagliflozin (JNJ-28431754); Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin, 100 mg, Drug: Canagliflozin, 300 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Canagliflozin, 100 mg; Assigned to Arm(s): Canagliflozin (JNJ-28431754) | Intervention Type: DRUG; Name: Canagliflozin, 300 mg; Assigned to Arm(s): Canagliflozin (JNJ-28431754)
D: Arm Label: Anagliptin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anagliptin | Arm Label: Sitagliptin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sitagliptin | Intervention Type: DRUG; Name: Anagliptin; Assigned to Arm(s): Anagliptin | Intervention Type: DRUG; Name: Sitagliptin; Assigned to Arm(s): Sitagliptin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Walnut Ingestion in Adults at Risk for Diabetes: Effects on Body Composition, Diet Quality, and Cardiac Risk Measures
Brief Summary: Proposed is a randomized, controlled, modified Latin square parallel design study with two treatment arms to examine walnut consumption effects on diet quality, body composition, and markers of cardiovascular risk in adults at risk for diabetes over a 6-month period. A modified crossover design (Latin square)27-29 will allow for both paired and unpaired analyses.


Options:
A: Arm Label: Full-Dose Nut; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Mixed tree nuts | Arm Label: Half-Dose Nut; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Whole wheat and bran muffin, Dietary Supplement: Mixed tree nuts | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Whole wheat and bran muffin | Intervention Type: DIETARY_SUPPLEMENT; Name: Whole wheat and bran muffin; Assigned to Arm(s): Control, Half-Dose Nut | Intervention Type: DIETARY_SUPPLEMENT; Name: Mixed tree nuts; Assigned to Arm(s): Full-Dose Nut, Half-Dose Nut
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: healthy life style education | Arm Label: B; Type: SHAM_COMPARATOR; Interventions: Behavioral: healthy life style education | Intervention Type: BEHAVIORAL; Name: healthy life style education; Assigned to Arm(s): A, B
C: Arm Label: Consumption of 42 g of salted peanuts; Type: EXPERIMENTAL; Interventions: Other: Consumption of 42 grams of peanuts daily | Arm Label: Consumption of 42 g of unsalted peanuts; Type: EXPERIMENTAL; Interventions: Other: Consumption of 42 grams of peanuts daily | Arm Label: Consumption of 42 g of spicy peanuts; Type: EXPERIMENTAL; Interventions: Other: Consumption of 42 grams of peanuts daily | Arm Label: Consumption of 42 g of honey peanuts; Type: EXPERIMENTAL; Interventions: Other: Consumption of 42 grams of peanuts daily | Arm Label: Consumption of 42 g of 3 diff. varieties; Type: EXPERIMENTAL; Interventions: Other: Consumption of 42 grams of peanuts daily | Arm Label: Consumption of 42 g of var. of types; Type: EXPERIMENTAL; Interventions: Other: Consumption of 42 grams of peanuts daily | Intervention Type: OTHER; Name: Consumption of 42 grams of peanuts daily; Assigned to Arm(s): Consumption of 42 g of 3 diff. varieties, Consumption of 42 g of honey peanuts, Consumption of 42 g of salted peanuts, Consumption of 42 g of spicy peanuts, Consumption of 42 g of unsalted peanuts, Consumption of 42 g of var. of types
D: Arm Label: Walnut Ad libitum diet; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Walnut Ad libitum diet | Arm Label: Walnut Calorie Controlled; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Walnut Calorie controlled | Intervention Type: DIETARY_SUPPLEMENT; Name: Walnut Ad libitum diet; Assigned to Arm(s): Walnut Ad libitum diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Walnut Calorie controlled; Assigned to Arm(s): Walnut Calorie Controlled

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis (AMS04)
Brief Summary: The primary goal of this study is to evaluate the effects of BAF312 (siponimod) on select immune and neuronal (nerve) cells by examining laboratory specimens (blood and/or spinal fluid) at multiple time points, prior to, and following the initiation of BAF312 or placebo treatment, in patients with Secondary Progressive Multiple Sclerosis (SPMS) who are enrolled in a clinical trial (NCT01665144) to evaluate the effectiveness and safety of BAF312.


Options:
A: Arm Label: BAF312 10 mg/2 mg; Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 2 mg/2 mg; Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 1.25 mg/2 mg; Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 .5 mg/2 mg; Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 .25 mg/2 mg; Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Intervention Type: DRUG; Name: BAF312; Assigned to Arm(s): BAF312 .25 mg/2 mg, BAF312 .5 mg/2 mg, BAF312 1.25 mg/2 mg, BAF312 10 mg/2 mg, BAF312 2 mg/2 mg
B: Arm Label: BAF312 10mg (period 1); Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 2 mg (period 1); Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 0.5 mg (period 1); Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 dose between 0.1 to 8 mg period 2; Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 dose between 0.1 - 8 mg period 2; Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: Placebo (period 1, 2); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BAF312; Assigned to Arm(s): BAF312 0.5 mg (period 1), BAF312 10mg (period 1), BAF312 2 mg (period 1), BAF312 dose between 0.1 - 8 mg period 2, BAF312 dose between 0.1 to 8 mg period 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (period 1, 2)
C: Arm Label: Subjects Assigned to BAF312; Type: N/A; Interventions: Procedure: Blood Draw, Procedure: CSF collection by lumbar puncture (Optional) | Arm Label: Subjects Assigned to Placebo (Controls); Type: N/A; Interventions: Procedure: Blood Draw, Procedure: CSF collection by lumbar puncture (Optional) | Intervention Type: PROCEDURE; Name: Blood Draw; Assigned to Arm(s): Subjects Assigned to BAF312, Subjects Assigned to Placebo (Controls) | Intervention Type: PROCEDURE; Name: CSF collection by lumbar puncture (Optional); Assigned to Arm(s): Subjects Assigned to BAF312, Subjects Assigned to Placebo (Controls)
D: Arm Label: Siponimod (BAF312); Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BAF312; Assigned to Arm(s): Siponimod (BAF312) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Granulocyte Colony-stimulating Factor(G-CSF) in the Treatment of Hepatic Failure: a Prospective Randomized Controlled Clinical Study
Brief Summary: This study evaluates the Granulocyte colony-stimulating factor (G-CSF) in the treatment of Acute on Chronic Liver Failure in adult. Half participants will receive G-CSF and standard treatment in combination, while half participants will receive standard treatment.


Options:
A: Arm Label: standard medical therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: standard medical therapy | Arm Label: G-CSF; Type: ACTIVE_COMPARATOR; Interventions: Drug: standard medical therapy, Drug: G-CSF | Arm Label: G-CSF plus growth hormone; Type: ACTIVE_COMPARATOR; Interventions: Drug: standard medical therapy, Drug: G-CSF, Drug: Growth Hormone | Intervention Type: DRUG; Name: standard medical therapy; Assigned to Arm(s): G-CSF, G-CSF plus growth hormone, standard medical therapy | Intervention Type: DRUG; Name: G-CSF; Assigned to Arm(s): G-CSF, G-CSF plus growth hormone | Intervention Type: DRUG; Name: Growth Hormone; Assigned to Arm(s): G-CSF plus growth hormone
B: Arm Label: Standard Medical Therapy + G CSF Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: G-CSF | Arm Label: Standard Medical Therapy + Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: G-CSF; Assigned to Arm(s): Standard Medical Therapy + G CSF Therapy | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Standard Medical Therapy + Placebo
C: Arm Label: Granulocyte colony-stimulating factor; Type: EXPERIMENTAL; Interventions: Drug: Granulocyte colony-stimulating factor, Drug: standard treatment | Arm Label: standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: standard treatment | Intervention Type: DRUG; Name: Granulocyte colony-stimulating factor; Assigned to Arm(s): Granulocyte colony-stimulating factor | Intervention Type: DRUG; Name: standard treatment; Assigned to Arm(s): Granulocyte colony-stimulating factor, standard treatment
D: Arm Label: G-CSF+EPO; Type: ACTIVE_COMPARATOR; Interventions: Drug: G-CSF+EPO | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: G-CSF+EPO; Assigned to Arm(s): G-CSF+EPO | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Prospective Trial of a Mobile Health Application for Asthma Self-Management
Brief Summary: The investigators aim to study the clinical efficacy of a mobile health application, AsthmaCare, and it's impact on long term health outcomes for asthma. AsthmaCare is a novel application developed by members of the study team that was previously studied in a pilot study of 21 children/teenagers 9-16 years old. During the 30 day pilot study, there was universal usage and acceptance by all participants of this novel form of technology and asthma management. This current study aims to measure clinical outcomes for users of the app.


Options:
A: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Device: Electronic Monitoring with audio reminders and additional support | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Electronic Monitoring with audio reminders and additional support; Assigned to Arm(s): Intervention group
B: Arm Label: CampAir Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: CampAir | Arm Label: Information and Referral Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Information and Referral | Intervention Type: BEHAVIORAL; Name: CampAir; Assigned to Arm(s): CampAir Intervention | Intervention Type: BEHAVIORAL; Name: Information and Referral; Assigned to Arm(s): Information and Referral Control
C: Arm Label: AsthmaCare intervention; Type: EXPERIMENTAL; Interventions: Other: AsthmaCare mobile health application | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: Asthma education | Intervention Type: OTHER; Name: AsthmaCare mobile health application; Assigned to Arm(s): AsthmaCare intervention | Intervention Type: OTHER; Name: Asthma education; Assigned to Arm(s): Control group
D: Arm Label: Intervention Arm; Type: EXPERIMENTAL; Interventions: Other: ASTHMAXcel App | Arm Label: Usual Care Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: ASTHMAXcel App; Assigned to Arm(s): Intervention Arm

Answer: C